# C_2023048EN.01004401.xml

| 8.2.2023 | EN | Official Journal of the European Union | C 48/44 |
| --- | --- | --- | --- |

8.2.2023

EN

Official Journal of the European Union

C 48/44

---

Prior notification of a concentration

(Case M.10997 – NB / ARDIAN / MEDIOLANUM / NEOPHARMED)

(Text with EEA relevance)

(2023/C 48/08)

1.

This notification concerns the following undertakings:

| — | Ardian France S.A. (France), |
| --- | --- |

—

Ardian France S.A. (France),

| — | NB Renaissance Partners Holdings S.à r.l. (Luxembourg), controlled by Neuberger Berman Group, LLC (United States of America), |
| --- | --- |

—

NB Renaissance Partners Holdings S.à r.l. (Luxembourg), controlled by Neuberger Berman Group, LLC (United States of America),

| — | Mediolanum Farmaceutici S.p.A. (Italy), |
| --- | --- |

—

Mediolanum Farmaceutici S.p.A. (Italy),

| — | Neopharmed Gentili S.p.A. (Italy). |
| --- | --- |

—

Neopharmed Gentili S.p.A. (Italy).

Ardian France S.A., NB Renaissance Partners Holdings S.à r.l. and Mediolanum Farmaceutici S.p.A. will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of Neopharmed Gentili S.p.A.

The concentration is accomplished by way of purchase of shares.

2.

| — | Ardian France S.A. is a French private equity company, which manages and advises, through its subsidiaries, a number of investment funds, |
| --- | --- |

—

Ardian France S.A. is a French private equity company, which manages and advises, through its subsidiaries, a number of investment funds,

| — | NB Renaissance Partners Holdings S.à r.l. is part of the Neuberger Berman group, which provides a broad range of investment solutions, |
| --- | --- |

—

NB Renaissance Partners Holdings S.à r.l. is part of the Neuberger Berman group, which provides a broad range of investment solutions,

| — | Mediolanum Farmaceutici S.p.A. is an Italian-based holding company mainly active, through its subsidiaries, in the pharmaceutical and contract manufacturing organization sectors, |
| --- | --- |

—

Mediolanum Farmaceutici S.p.A. is an Italian-based holding company mainly active, through its subsidiaries, in the pharmaceutical and contract manufacturing organization sectors,

| — | Neopharmed Gentili S.p.A is active in the commercialization of finished dose pharmaceutical products and supplements in various therapeutic areas, sale of medical devices and cosmetics. |
| --- | --- |

—

Neopharmed Gentili S.p.A is active in the commercialization of finished dose pharmaceutical products and supplements in various therapeutic areas, sale of medical devices and cosmetics.

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10997 – NB / ARDIAN / MEDIOLANUM / NEOPHARMED

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---